Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use
https://doi.org/10.14412/2074-2711-2015-1-75-79
Abstract
The paper generalizes the experience with one of the main original drugs for the treatment of multiple sclerosis (MS) – glatiramer acetate (GA, Copaxone®, Teva) in large Russian MS centers. The performed analysis of clinical trials suggests the high efficacy and favorable safety profile of the drug. The fact that patents for a number of effective and widely used original drugs, including those for agents from a group of immunomodulators, used to treat MS expire is one of the features of the current development of medicine. Due to the fact that most of them belong to interferons-β, i.e. biologicals, or structurally close to nonbiological complex drugs, the authors discuss the need to conduct comparative clinical trials of the original drug and follow-on glatiramoids with measured endpoints that can be used to establish their efficacy, safety, and evidence for therapeutic equivalence in order to examine their potential interchangeability.
About the Authors
I. D. Stolyarov
N.P. Bekhtereva Institute of Human Brain, Russian Academy of Sciences, Saint Petersburg, Russia 9, Academician Pavlov St., Saint Petersburg 197376
Russian Federation
Russian Federation
A. M. Petrov
N.P. Bekhtereva Institute of Human Brain, Russian Academy of Sciences, Saint Petersburg, Russia 9, Academician Pavlov St., Saint Petersburg 197376
Russian Federation
Russian Federation
M. V. Votintseva
N.P. Bekhtereva Institute of Human Brain, Russian Academy of Sciences, Saint Petersburg, Russia 9, Academician Pavlov St., Saint Petersburg 197376
Russian Federation
Russian Federation
I. G. Nikiforova
N.P. Bekhtereva Institute of Human Brain, Russian Academy of Sciences, Saint Petersburg, Russia 9, Academician Pavlov St., Saint Petersburg 197376
Russian Federation
Russian Federation
References
1. Столяров ИД, Бойко АН, редакторы. Рассеянный склероз: диагностика, лечение, специалисты. Санкт-Петербург: ЭЛБИ-СПб; 2008. 320 с. [Stolyarova ID, Boiko AN, editors. Rasseyannyi skleroz: diagnostika, lechenie, spetsialisty [Multiple sclerosis: diagnosis, treatment, specialists]. Saint-Petersburg: ELBI-SPB; 2008. 320 p.].
2. Завалишин ИА, Шварц ГЯ, редакторы. Копаксон в лечении рассеянного склероза (сборник статей). Москва: Миклош; 2007. 310 с. [Zavalishin IA, Shvarts GYa, editors. Kopakson v lechenii rasseyannogo skleroza (sbornik statei) [Copaxone in the treatment of multiple sclerosis (collection of articles)]. Moscow: Miklosh; 2007. 310 p.].
3. Шварц ГЯ, Раменская ГВ. Анализ причин практической невозможности создания генериков Копаксона. Химико-фармацевтический журнал 2012;46(11):1–6. [Shvarts GYa, Ramenskaya GV. Analysis of the reasons for the impossibility of creating Copaxone generics. Khimiko-farmatsevticheskii zhurnal 2012;46(11):1–6. (In Russ.)].
4. Varkony H, Weinstein V, Klinger E, et al. The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother. 2009 Mar;10(4):657–68. doi: 10.1517/14656560902802877.
5. Nicholas JM. Complex drugs and biologics: scientific and regulatory challenges for followon products. Drug Inf J. 2012;46(2):197–206
6. Farina C, Weber MS, Meinl E, et al. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 2005 Sep;4(9):567–75.
7. Yong VW. Differential mechanisms of action of interferon beta and glatiramer acetate in MS. Neurology. 2002 Sep 24;59(6):802–8.
8. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001 Mar 27;56(6):702–8.
9. Шмидт ТН, Яхно НН. Рассеянный склероз. Руководство для врачей. Москва: МЕДпресс-информ; 2012. 272 с. [Shmidt TN, Yakhno NN. Rasseyannyi skleroz. Rukovodstvo dlya vrachei [Multiple sclerosis. A guide for physicians]. Moscow: MEDpress-inform; 2012. 272 p.].
10. Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol. 2007;79:537–70.
11. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med. 2005 Apr;11(4 Suppl):S69–76.
12. Aharoni R, Kayhan B, Eilam R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brainderived neurotrophic factor in situ. Proc Natl Acad Sci USA. 2003 Nov 25;100(24): 14157–62. Epub 2003 Nov 12.
13. Aharoni R, Herschkovitz A, Eilam R, et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2008 Aug 12;105(32):11358–63. doi: 10.1073/pnas. 0804632105. Epub 2008 Aug 4.
14. Schellekens H, Klinger E, Mü hlebach S, et al. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol. 2011 Feb;59(1):176–83. doi: 10.1016/j.yrtph.2010. 09.021. Epub 2010 Oct 14.
15. Bakshi S, Chalifa-Caspi V, Plaschkes I, et al. Gene expression analysis reveals functional pathways of glatiramer acetate activation. Expert Opin Ther Targets. 2013 Apr;17(4):351–62. doi: 10.1517/14728222.2013.778829. Epub 2013 Mar 8.
16. Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013 Jun;73(6):705–13. doi: 10.1002/ana.23938. Epub 2013 Jun 28.
17. Переседова АВ, Завалишин ИА, Адарчева ЛС и др. Глатирамера ацетат (Копаксон) в лечении рассеянного склероза. Результаты длительного применения: возникающие вопросы и направления дальнейших исследований. Нервные болезни. 2012;(4):26–30. [Peresedova AV, Zavalishin IA, Adarcheva LS, et al. Glatiramer acetate (Copaxone) in the treatment of multiple sclerosis. The results of long-term use: issues and directions for further research. Nervnye bolezni. 2012;(4):26–30. (In Russ.)].
18. Бойко АН, Давыдовская МВ, Демина ТЛ и др. Эффективность и переносимость глатирамера ацетата (копаксона) при длительном использовании: 10-летний опыт Московского городского центра рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;(2):86–92. [Boiko AN, Davydovskaya MV, Demina TL, et al. The efficacy and tolerability of glatiramer acetate (Copaxone) in extended use: a 10-year experience of the Moscow city center for multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2012;(2):86–92. (In Russ.)].
19. Stoliarov I, Ilves A, Prakhova L, et al. Effect of Glatiramer acetate therapy on regional cerebral metabolic abnormalities in MS patients (pilot study). Multiple Sclerosis 2002; 8 (Suppl.1): S48.
20. Петров АМ, Минеев КК, Ивашкова ЕВ и др. К вопросу о когнитивных нарушениях и изменении цитокинового профиля при ремиттирующем рассеянном склерозе. Нейроиммунология. 2008;6(3–4):41–4. [Petrov AM, Mineev KK, Ivashkova EV, et al. To the question of cognitive impairment and change in cytokine profile in remitting multiple sclerosis. Neiroimmunologiya. 2008;6(3–4):41–4. (In Russ.)].
21. Towfic F, Funt JM, Fowler KD, et al. Comparing the biological impact of glatiramer acetate with the biological impact of a generic. PLoS One. 2014 Jan 8;9(1):e83757. doi: 10.1371/journal.pone.0083757. eCollection 2014. 22. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012 Apr;122(4):1180–8. doi: 10.1172/JCI58649. Epub 2012 Apr 2.
22. Hong J, Li N, Zhang X, et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA. 2005 May 3;102(18):6449–54. Epub 2005 Apr 25.
23. http://clinicaltrials.gov/ct2/show/ record/NCT01489254?term=GTR001&rank=1 25. Завалишин ИА, Пирадов МА, Бойко АН и др., редакторы. Аутоиммунные заболевания в неврологии. Клиническое руководство. Т.1. Москва: РООИ «Здоровье человека»; 2014. 400 с. [Zavalishin IA, Piradov MA, Boiko AN, et al., editors. Autoimmunnye zabolevaniya v nevrologii. Klinicheskoe rukovodstvo [Autoimmune diseases in neurology. Clinical guide]. Moscow: ROOI «Zdorov'e cheloveka»; 2014. Vol. 1. 400 p.]
Review
For citations:
Stolyarov ID, Petrov AM, Votintseva MV, Nikiforova IG. Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(1):75-79. (In Russ.) https://doi.org/10.14412/2074-2711-2015-1-75-79
Views:
1011
Email this article 